Details for Patent: 9,266,912

Which drugs does patent 9,266,912 protect, and when does it expire?

Patent 9,266,912 protects TAVALISSE and is included in one NDA.

This patent has thirty-eight patent family members in twenty-nine countries.

Summary for Patent: 9,266,912

Title:	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract:	The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s):	Singh; Rajinder (Belmont, CA), Bhamidipati; Somasekhar (Foster City, CA), Masuda; Esteban (Menlo Park, CA), Sun; Thomas (Palo Alto, CA), Stella; Valentino J. (Lawrence, KS)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	14/310,312
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,266,912

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018		RX	Yes	No						TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes						TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

International Family Members for US Patent 9,266,912

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E451381
Australia	2006206458
Brazil	PI0606318
Canada	2591948
China	101115761